- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells
© Fadnes et al; licensee BioMed Central Ltd. 2009
Received: 17 September 2008
Accepted: 15 June 2009
Published: 15 June 2009
Cationic antimicrobial peptides (CAPs) with antitumor activity constitute a promising group of novel anticancer agents. These peptides induce lysis of cancer cells through interactions with the plasma membrane. It is not known which cancer cell membrane components influence their susceptibility to CAPs. We have previously shown that CAPs interact with the two glycosaminoglycans (GAGs), heparan sulfate (HS) and chondroitin sulfate (CS), which are present on the surface of most cells. The purpose of this study was to investigate the role of the two GAGs in the cytotoxic activity of CAPs.
Various cell lines, expressing different levels of cell surface GAGs, were exposed to bovine lactoferricin (LfcinB) and the designer peptide, KW5. The cytotoxic effect of the peptides was investigated by use of the colorimetric MTT viability assay. The cytotoxic effect on wild type CHO cells, expressing normal amounts of GAGs on the cell surface, and the mutant pgsA-745, that has no expression of GAGs on the cell surface, was also investigated.
We show that cells not expressing HS were more susceptible to CAPs than cells expressing HS at the cell surface. Further, exogenously added heparin inhibited the cytotoxic effect of the peptides. Chondroitin sulfate had no effect on the cytotoxic activity of KW5 and only minor effects on LfcinB cytotoxicity.
Our results show for the first time that negatively charged molecules at the surface of cancer cells inhibit the cytotoxic activity of CAPs. Our results indicate that HS at the surface of cancer cells sequesters CAPs away from the phospholipid bilayer and thereby impede their ability to induce cytolysis.
Cationic antimicrobial peptides (CAPs), also termed host defense peptides, play a part in the innate immune system . CAPs can be assigned into two broad groups based on their target specificity, one group comprising antimicrobial activity, such as defensins [2, 3], and cecropins , which have specificity for prokaryotic cell membranes, and a second group, the venom peptides with activity against both prokaryotic and eukaryotic cell membranes e.g. melittin  and mastoparan . In addition, some of the CAPs show selective activity against cancer cells. These peptides act via a non-receptor-mediated pathway and constitute a promising group of novel anticancer agents with a new mode of action and a broad spectrum of anticancer activity. Several studies, included our earlier reported in vivo studies, indicate that CAPs may have a potential for local treatment of solid tumors [7–10]. Compared to conventional chemotherapy these CAPs display a higher specificity for cancer cells versus normal cells [11, 12]. In addition, the peptides are able to kill cancer cells that have become resistant to conventional chemotherapeutics [13–16]. It has also been reported that certain CAPs have the potential to enhance the cytotoxic activity of different chemotherapeutics against multi-drug resistant tumor cells [13–15]. The reason why CAPs display activity against chemoresistant cancer cells probably lies in their rapid mode of action against the plasma membrane, resulting in lysis of the cells . Most of the CAPs selective for cancer cells interact with the target membrane through the "carpet model", where the peptides align parallel to the outer membrane surface and permeate the membrane after a threshold concentration of peptides have been reached [18, 19]. In addition, some CAPs can also trigger apoptosis in cancer cells via mitochondrial membrane disruption .
It is not yet clarified which components in the plasma membrane render cancer cells more susceptible to CAPs than non-malignant cells. Due to the cationic nature of the peptides, the interaction with the cell surface of the target cells is most likely facilitated by negatively charged molecules in the plasma membrane. Whereas the plasma membranes of non-malignant eukaryotic cells consist primarily of zwitterionic and neutral phospholipids , a number of studies have revealed that the outer membrane leaflet of cancer cells is more negatively charged than their normal counterparts. An elevated expression of the anionic phospholipid phosphatidylserine in the outer leaflet of the plasma membrane has been found in several types of cancer cell lines [22–25]. Alterations in the carbohydrate portion of glycoproteins and glycolipids, including increased sialylation, also contributes to a more negatively charged tumor cell surface . The enhanced expression of terminal sialic acids on cell surface N-linked glycans and O-linked glycans has been reported as a characteristic in a variety of cancers .
Proteoglycans (PGs) are also expressed on the cell surface. These are characterized by highly negatively charged glycosaminoglycan (GAG) side chains attached to a core protein . Two major classes of GAG side chains are heparan sulfate (HS) and chondroitin sulfate (CS). These molecules consist of a linear repeat of up to 100 disaccharide units [29, 30]. Both HS and CS are highly sulfated with an average number of approximately 1.2 and 1.0 negatively charged sulfate groups per disaccharide unit, respectively [31, 32]. The sulfate groups make therefore the PGs some of the most anionic molecules on the cell surface. It has been shown that several cancer cells have a different expression of cell surface PGs, compared to their normal counterpart cells [33–35]. In addition, it has been shown that the degree and pattern of sulfation of the GAG chains may be altered during malignant transformation [36, 37].
One member of the CAP family is bovine lactoferricin (LfcinB). This peptide displays cytotoxic activity against a variety of cancer cells in vitro, without harming normal cells [8, 38]. In addition, LfcinB is able to prevent tumor growth and metastasis in several mouse models [7, 8, 39]). Previous studies have revealed that LfcinB induces cell death in tumor cells by targeting the plasma membrane and after internalization, the mitochondria .
We have previously shown that LfcinB binds to GAGs . Since the fundamental activity of antimicrobial peptides stems from their ability to interact with negatively charged membrane molecules, we hypothesized that GAGs at the surface of target cells may interact with CAPs and enhance their cytotoxic activity. In the present study the role of GAGs in the cytotoxic activity of LfcinB was thus investigated. LfcinB is a 25-mer peptide with a disulfide bridge that forms a stabilized amphipatic β-sheet structure. In addition, the KW5 peptide, a 21-mer peptide designed to adopt an idealized amphipathic α-helix was also included in the study.
The LfcinB peptide was provided by the Centre for Food Technology (Queensland, Australia). All Fmoc-amino acids, Fmoc-resins and chemicals used during peptide synthesis, cleavage and precipitation were purchased from PerSeptive (Hertford, UK), Fluka (Buchs, Switzerland) and Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS) was obtained from Biochrom KG (Berlin, Germany), and L-glutamine from Gibco (Paisley, Scotland). MTT (3-(4, 5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide) was obtained from Sigma-Aldrich (Oslo, Norway). Heparitinase (EC 22.214.171.124) and chondroitinase ABC (EC 126.96.36.199) were from Seikagaku Corporation (Chuo-ku, Tokyo, Japan). Heparin (H-3393) and chondroitin sulfate (C-4384) were obtained from Sigma-Aldrich (Oslo, Norway). [35S]Sulfate (code SJS-1) was purchased from Amersham Biosciences (Buckinghamshire, England).
The lymphoma cell lines KMS-5, KMM-1 and Sudhl-4 were a kind gift from Mark Raffeld, Hematophathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD. The lymphoma cell lines Raji and Ramos were provided by Dr. Michael Norcross, Division of Hematologic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, while the lymphoma cell line U-266, colon carcinoma cell line HT-29 and the melanoma cell line FEMX were purchased from ATCC. Jeffery D. Esko, Department of Cellular and Molecular Medicine, University of California, San Diego, USA, kindly provided us with the mutant Chinese hamster ovary cell line pgsA-745, which does not express GAGs at the cell surface, as well as the wild type CHO-K1 that expresses normal amounts of GAGs [41, 42].
Peptide synthesis, purification and analysis
The peptide KW5, ((KAAKKAA)3 W 7,9,16), was synthesized by solid-phase methods using standard Fmoc chemistry on a Pioneer Peptide synthesizer (Applied Biosystems, Foster City, CA). Crude peptides were purified by preparative RP-HPLC (Waters, Milford, MA) using a C18 column (Delta-Pak™ C18, 100 Å, 15 μm, 25–100 mm), and analyzed on an analytical C18 HPLC column (Delta-Pak™ C18, 100 Å, 5 μm, 3.9 × 150 mm) (Waters, Milford, MA). The purity of the peptides was found to be > 95%. Peptide characterization was done by positive ion electrospray ionization mass spectrometry on a VG quattro quadrupole mass spectrometer (VG Instruments Inc., Altringham, UK).
The HT-29 and FEMX cell lines were maintained as monolayer cultures in RPMI-1640 supplemented with 10% (v/v) FBS and 1% L-glutamine, while the CHO-K1 and pgsA-745 cell lines were cultured in HAM's-F12 supplemented with 10% (v/v) FBS and 1% L-glutamine. All the lymphoma cell lines were grown in suspension in RPMI-1640 medium supplemented with 10% (v/v) FBS and 1% L-glutamine. All cells were grown in tissue culture flasks in humidified atmosphere of 95% air and 5% CO2 at 37°C.
The colorimetric MTT viability assay was used to investigate the cytotoxic effect of the peptides. The FEMX and HT-29 cells were seeded at a concentration of 2 × 105 cell/ml, and the CHO-K1 and pgsA-745 cells at a concentration of 1.5 × 105 cell/ml in a volume of 0.1 ml in 96-well plates. The cells were allowed to adhere overnight in complete medium. Before adding different concentrations of the peptides (1–500 μg/ml) to the cells, the culture medium was removed and the cells were washed twice in serum-free culture medium. The non-adherent lymphoma cell lines were seeded at a density of 4 × 105 cells/ml using serum-free medium. The cells were incubated with the LfcinB peptide at 37°C for 24 h or with the KW5 peptide for 30 min. Due to our previous structure-activity relationship studies on lactoferrrin and LfcinB [7, 43] structural parameters important for lytic activity against cancer cells are optimized in de novo designed peptides. Hence, the KW5 peptide is more active and kills cancer cells more efficiently than LfcinB. Cells in serum-free medium alone were used as a negative control whereas cells treated with 1% Triton X-100 in serum-free medium were used as a positive control for 100% cell death. After incubation, 10 μl (adherent cells) or 20 μl (non-adherent cells) MTT-solution (5 mg MTT per ml phosphate buffered saline) was added to each well and the incubation was continued for 2 h. A volume of 80 μl or 130 μl per well was removed from the non-adherent and the adherent cells, respectively. In order to dissolve the formazan crystals, 100 μl of 0.04 M HCl in isopropanol was added and the plates were shaken for 1 h on a Thermolyne Roto Mix (Dubuque, IA) at room temperature. The optical density was measured on a microtitre plate reader (Thermomax Molecular Devises, NJ). Cell survival was determined from the ΔA590 nm relative to the negative control (100% living cells) and expressed as 50% inhibitory concentration (IC50).
Sodium chlorate treatment
The FEMX and HT-29 cells were seeded at a concentration of 2 × 105 cell/ml in a volume of 0.1 ml in 96-well plates. The cells were incubated for 24 h at 37°C in complete medium supplemented with 30 mM sodium chlorate, which decreases sulfation by inhibiting ATP-sulphurylase . After the treatment period the culture medium containing sodium chlorate was removed and the cells were washed with serum free RMPI-1640 medium before the cytotoxic activity of the peptides were investigated using the MTT assay described above.
Heparitinase purified from Flavobacterium heparinum was used for enzymatic cleavage of cell surface HS. Heparitinase (0.1 U) was dissolved in 100 μl 0.1% M Tris acetate (pH 7.3). FEMX and HT-29 cells were seeded at a concentration of 1 × 105 cell/ml in a volume of 0.1 ml in 96-well plates. After 48 h at 37°C the cells were treated with 0, 01 U heparitinase in serum free medium for 2 h at 37°C. Thereafter some cell cultures were washed with serum free medium before the cytotoxic activity of the peptides was investigated. In other cell cultures heparitinase was present during the whole peptide incubation period.
Radiolabeling and isolation of 35S-labeled macromolecules
Cell cultures were radiolabeled for 20 h by adding [35S]sulfate to a final concentration of 50 μCi/ml at the time of cell plating. To be able to compare the amount of 35S-labeled macromolecules synthesized by the different cell lines, the cells were cultured at same level of sub-confluence. After the incubation time, the plasma membrane-associated 35S-labeled macromolecules were harvested by washing the cells twice with serum free-medium and subsequently incubated for 15 min at 37°C in the presence of 10 μg/ml of trypsin . Free [35S]sulfate was removed by gel filtration on Sephadex G50 Fine columns (bed volume 4 ml, equilibrated with 0.5 M Tris/HCl, pH 8.0 and 0.15 M NaCl and eluted with dH2O). Aliquots from the membrane fractions were analyzed for radioactivity in a scintillation counter after the addition of Ultima Gold XR scintillation fluid. The rest of the material was immediately frozen and stored until further analysis.
Alkali treatment and gel chromatography
The 35S-labeled macromolecules were subjected to alkali treatment (0.5 M NaOH over night at 45°C, followed by neutralization with 0.5 M HCl), resulting in liberation of free 35S-labeled GAG chains. The 35S-labeled macromolecules were subjected to Superose 6 gel chromatography both before and after alkali treatment. Markers for void (Vo) and total volume (Vt) were blue dextran and [35S]sulfate, respectively. The columns were run in 4 M guanidine-HCl with 0.05 M sodium acetate, pH 5.8. Fractions were collected and the radioactivity counted in a scintillation counter.
Selective PG degradation
The 35S-labeled macromolecules were subjected to enzymatic treatment with chondroitinase ABC (cABC), which depolymerizes CS. Incubations with cABC were performed at 37°C overnight with 0.01 U enzyme per sample in 0.05 M Tris/HCl, 0.05 M sodium acetate, pH 8.0. The samples were analyzed on Sephadex G-50 Fine columns (bed volume 4 ml, equilibrated and eluted with the Tris/HCl buffer). In addition, parallel samples were subjected to HNO2 treatment at pH 1.5, in order to degrade the HS chains . The samples were analyzed by Sephadex G-50 Fine columns (bed volume 4 ml, equilibrated and eluted with dH2O). Aliquots from the collected fractions where analyzed for radioactivity in a scintillation counter after the addition of Ultima Gold XR scintillation fluid.
Cytotoxic effect of the peptides
The cytotoxic effect of LfcinB and KW5 against FEMX and HT-29 cells.
Ratio(IC50)HT-29 cells/FEMX cells
40 ± 7
148 ± 8
30 ± 3
55 ± 14
Sodium Chlorate treatment of the target cells enhances the cytotoxic effect of the peptides
GAG deficient CHO cells were more susceptible for the peptides
Determination of the type of GAGs at the cell surface
Exogenous heparin inhibited the effect of the peptides
Lymphoma cells expressing HS at the cell surface were less susceptible to the cationic peptides
The cytotoxic effect of LfcinB against lymphoma cell lines expressing different levels of HS.
aCell surface HS
HT-29 cells synthesize larger PGs than FEMX cells
It is known that a variety of lytic peptides show a selective cytotoxic activity against tumor cells compared to normal cells. It is believed that this selectivity is due to a more negatively charged cell surface of the tumor cells, but the exact mechanism is not known. The plasma membrane of almost all mammalian cells contains PGs substituted with GAG chains. The GAGs are highly anionic due to a large number of negatively charged sulfate groups . We have previously shown that LfcinB and other lytic peptides bind to GAGs  and we therefore hypothesized that cell surface GAGs increase binding and therefore in accordance with work on other anionic membrane components increase the cytotoxic activity of CAPs. However, the present study showed that cell surface GAGs inhibited the cytotoxic effect of LfcinB and the designer lytic peptide, KW5.
In the initial experiments we used two cell lines which express different amounts of GAGs at the cell surface; the melanoma cell line FEMX and the colon carcinoma cell line HT-29. Both peptides displayed higher cytotoxic activity against the FEMX cells, which express a larger amount of GAGs compared to the HT-29 cells. This result is in agreement with previous studies showing that an increased negative charge on the cell surface of target cells enhances the cytotoxic activity of lytic peptides [50, 51]. To confirm our hypothesis that it is the negatively charged sulfate groups on the GAG chains that mediate the binding of the peptides, the sulfation of the GAGs was reduced by adding sodium chlorate to the culture medium before the cells were exposed to the peptides. Chlorate reduces the overall sulfation of GAGs by competing with sulfate ions for binding to ATP-sulfyrolase . Interestingly, we found that the peptides displayed a significantly greater cytotoxic activity against chlorate-treated cells compared to non-treated cells, indicating that the negatively charged GAGs at the cell surface actually reduce the cytotoxic activity of the peptides. Previous studies have shown that incubating cells with sodium chlorate only leads to a partial reduction of the sulfation of the GAG chains . This may explain why the effect of chlorate on the cytotoxic effect was only moderate.
In order to investigate the involvement of GAGs more directly, the cytotoxic activity of the peptides was studied with wild type and GAG-defective CHO cells . These cells have been widely used to study the role of cell surface GAGs in various processes such as viral infection, growth factor signaling and cell adhesion . The pgsA-745 cells have defective xylosyltransferase, an enzyme necessary for biosynthesis of HS and CS . The higher cytotoxic activity of the peptides against the GAG deficient pgsA-745 cells compared to the wild type CHO cells expressing normal levels of GAGs at the cell surface clearly indicate that GAGs have an inhibitory effect on the cytotoxic activity of these peptides. This finding is in contrast to reports about other anionic cell surface molecules which have been shown to enhance the anticancer activity of CAPs [50, 51].
Cell surface PGs may be substituted with different types of GAG chains, either HS or CS . We have previously shown that LfcinB and other lytic peptides bind with higher affinity to HS than CS . We therefore examined the expression pattern of GAGs on the FEMX and HT-29 cells. We found that the FEMX cells expressed cell surface PGs mostly substituted with CS, whereas the PGs at the surface of HT-29 cells were mostly substituted with HS. This expression profile is consistent with previous reports showing that malignant melanoma cells have a high expression of CSPGs , while the HT-29 cells has a high expression of HSPGs. . The lower cytotoxic activity of the peptides against the HT-29 cells compared to the FEMX cells therefore suggests that the inhibitory effect of GAGs is attributed to HS and not CS. The addition of soluble heparin and CS to cell cultures is widely used to study the interaction between various molecules and cell surface HS and CS [57, 58]. In the present study we found that exogenously added heparin had a stronger inhibitory effect on the cytotoxic activity of the peptides, compared to CS. This experiment strongly supports the finding that it is HS, and not CS, that inhibits the cytotoxic activity of the peptides. The inhibitory effect of HS was further supported by the fact that lymphoma cells lacking HS at the cell surface were much more sensitive to LfcinB than lymphoma cells expressing cell surface HS.
An earlier finding showing that low-molecular heparin is less efficient in binding lactoferrin than normal sized heparin , indicates that the size of the GAG chains could be an important factor for the interaction with the peptides. In the present study we found the size of the PGs on the surface of the HT-29 cells to be larger than the PGs on the surface of the FEMX cells. Larger PGs may keep the lytic peptides at a longer distance from the phospholipid bilayer than smaller PGs. The size of the cell surface PGs may therefore influence the sensitivity of the cells for lytic peptides. In addition to the size of the proteoglycans the degree and pattern of sulfation of the GAG chains may also influence the level of interaction between the peptides and the GAG chains. If the peptides have high sequence specificity and requires a particular sulfation pattern in order to interact with the GAGs this would also affect their binding capacity as shown for growth factors [69, 70], antithrombin III  and matrix ligand .
It has been shown that phosphatidylserine  and sialic acid  found on the cell surface of tumor cells enhance the antitumor activity of CAPs. Phosphatidylserine is present at the outer leaflet of many cancer cell lines and a higher number of sialic acids is present on glycoproteins and glycolipids on cancer cells compared to normal cells. Thus, these smaller anionic molecules located closer to the phospholipid bilayer of the tumor cells might facilitate the activity of the peptides whereas the large PGs have an opposite effect.
Many studies have shown that poorly differentiated tumors have reduced expression levels of cell surface HSPGs , indicating that the biosynthesis of HS PGs is reduced in these tumors. The best studied cell surface proteoglycan is syndecan-1. In a wide range of carcinomas it has been shown that a low expression of syndecan-1 on tumor cell surfaces correlates with increasing metastatic potential and poor prognosis [73–75]. In addition to reduced synthesis, an increased degradation of cell surface HS may take place. Heparanase is a HS degrading enzyme released by several cell types . It has been found that many tumors overexpress heparanase . Further, increased expression of heparanase is correlated with the high metastatic capacity of tumor cells . Heparanase released by the tumor cells degrades HS both in the extracellular matrix and at the cell surface. Hence, the low level of cell surface HS found in many tumors can be a result of increased level of heparanase. Alterations in the expression pattern of HS at the surface of tumor cells, due to reduced biosynthesis of HS and/or increased expression of heparanase, can explain, at least partly, the fact that many cancer cells show increased susceptibility toward certain CAPs.
In the present study we show for the first time that negatively charged molecules on the surface of tumor cells can inhibit the antitumor activity of CAPs. Further studies should be done with other structurally different CAPs to conclude whether this is the case for all types of CAPs. We show that the cytotoxic activity was significantly reduced in cells expressing HS at the surface. Our results indicate that HS at the surface of cancer cells can sequester the CAPs away from the phospholipid bilayer and thereby hinder their ability to induce cytolysis. Previous studies have shown that low level of cell surface HS is correlated with high metastatic potential of cancer cells. Our results indicate that poorly differentiated tumors, with low expression of cell surface HS, are more susceptible to treatment with CAPs. To confirm this, the effect of CAPs on tumors with high and low HS expression should be explored with in vivo studies.
The financial support of Helse Nord, Lytix Biopharma and The Norwegian Cancer Society is greatly acknowledged. The authors wish to thank Prof. Masaki Yanagishita, Tokyo Medical and Dental University, for valuable discussions.
- Boman HG: Peptide antibiotics and their role in innate immunity. Annu Rev Immunol. 1995, 13: 61-92. 10.1146/annurev.iy.13.040195.000425.View ArticlePubMedGoogle Scholar
- Hultmark D, Engstrom A, Bennich H, Kapur R, Boman HG: Insect immunity: isolation and structure of cecropin D and four minor antibacterial components from Cecropia pupae. Eur J Biochem. 1982, 127 (1): 207-217. 10.1111/j.1432-1033.1982.tb06857.x.View ArticlePubMedGoogle Scholar
- Cornet B, Bonmatin JM, Hetru C, Hoffmann JA, Ptak M, Vovelle F: Refined three-dimensional solution structure of insect defensin A. Structure. 1995, 3 (5): 435-448. 10.1016/S0969-2126(01)00177-0.View ArticlePubMedGoogle Scholar
- Li ZQ, Merrifield RB, Boman IA, Boman HG: Effects on electrophoretic mobility and antibacterial spectrum of removal of two residues from synthetic sarcotoxin IA and addition of the same residues to cecropin B. FEBS Lett. 1988, 231 (2): 299-302. 10.1016/0014-5793(88)80837-8.View ArticlePubMedGoogle Scholar
- Bechinger B: Structure and functions of channel-forming peptides: magainins, cecropins, melittin and alamethicin. J Membr Biol. 1997, 156 (3): 197-211. 10.1007/s002329900201.View ArticlePubMedGoogle Scholar
- Polozov IV, Polozova AI, Tytler EM, Anantharamaiah GM, Segrest JP, Woolley GA, Epand RM: Role of lipids in the permeabilization of membranes by class L amphipathic helical peptides. Biochemistry. 1997, 36 (30): 9237-9245. 10.1021/bi970045l.View ArticlePubMedGoogle Scholar
- Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O: Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 2002, 22 (5): 2703-2710.PubMedGoogle Scholar
- Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Lokke C, Ponthan F, Johnsen JI, Sveinbjornsson B, Kogner P, et al: The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer. 2006, 119 (3): 493-500. 10.1002/ijc.21886.View ArticlePubMedGoogle Scholar
- Papo N, Shahar M, Eisenbach L, Shai Y: A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem. 2003, 278 (23): 21018-21023. 10.1074/jbc.M211204200.View ArticlePubMedGoogle Scholar
- Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L: RGD-Tachyplesin inhibits tumor growth. Cancer Res. 2001, 61 (6): 2434-2438.PubMedGoogle Scholar
- Dennison SR, Whittaker M, Harris F, Phoenix DA: Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci. 2006, 7 (6): 487-499. 10.2174/138920306779025611.View ArticlePubMedGoogle Scholar
- Mader JS, Hoskin DW: Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs. 2006, 15 (8): 933-946. 10.1517/135437188.8.131.523.View ArticlePubMedGoogle Scholar
- Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB: In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des. 2000, 15 (2): 151-160.PubMedGoogle Scholar
- Cruciani RA, Barker JL, Durell SR, Raghunathan G, Guy HR, Zasloff M, Stanley EF: Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes. Eur J Pharmacol. 1992, 226 (4): 287-296. 10.1016/0922-4106(92)90045-W.View ArticlePubMedGoogle Scholar
- Ohsaki Y, Gazdar AF, Chen HC, Johnson BE: Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 1992, 52 (13): 3534-3538.PubMedGoogle Scholar
- Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003, 24 (7): 945-953. 10.1016/S0196-9781(03)00194-3.View ArticlePubMedGoogle Scholar
- Matsuzaki K: Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta. 1999, 1462 (1–2): 1-10.View ArticlePubMedGoogle Scholar
- Pouny Y, Shai Y: Interaction of D-amino acid incorporated analogues of pardaxin with membranes. Biochemistry. 1992, 31 (39): 9482-9490. 10.1021/bi00154a022.View ArticlePubMedGoogle Scholar
- Oren Z, Shai Y: Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers. 1998, 47 (6): 451-463. 10.1002/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, et al: Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999, 5 (9): 1032-1038. 10.1038/12469.View ArticlePubMedGoogle Scholar
- Yeaman MR, Yount NY: Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev. 2003, 55 (1): 27-55. 10.1124/pr.55.1.2.View ArticlePubMedGoogle Scholar
- Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ: Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991, 51 (11): 3062-3066.PubMedGoogle Scholar
- Bucana CD, Hoyer LC, Schroit AJ, Kleinerman E, Fidler IJ: Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro. Am J Pathol. 1983, 112 (1): 101-111.PubMedPubMed CentralGoogle Scholar
- Sugimura M, Donato R, Kakkar VV, Scully MF: Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces. Blood Coagul Fibrinolysis. 1994, 5 (3): 365-373.PubMedGoogle Scholar
- Rao LV, Tait JF, Hoang AD: Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity. Thromb Res. 1992, 67 (5): 517-531. 10.1016/0049-3848(92)90013-Z.View ArticlePubMedGoogle Scholar
- Kim YJ, Varki A: Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997, 14 (5): 569-576. 10.1023/A:1018580324971.View ArticlePubMedGoogle Scholar
- Dube DH, Bertozzi CR: Glycans in cancer and inflammation – potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005, 4 (6): 477-488. 10.1038/nrd1751.View ArticlePubMedGoogle Scholar
- Kjellen L, Lindahl U: Proteoglycans: structures and interactions. Annu Rev Biochem. 1991, 60: 443-475. 10.1146/annurev.bi.60.070191.002303.View ArticlePubMedGoogle Scholar
- Sugahara K, Mikami T, Uyama T, Mizuguchi S, Nomura K, Kitagawa H: Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate. Curr Opin Struct Biol. 2003, 13 (5): 612-620. 10.1016/j.sbi.2003.09.011.View ArticlePubMedGoogle Scholar
- Tkachenko E, Rhodes JM, Simons M: Syndecans: new kids on the signaling block. Circ Res. 2005, 96 (5): 488-500. 10.1161/01.RES.0000159708.71142.c8.View ArticlePubMedGoogle Scholar
- Rabenstein DL: Heparin and heparan sulfate: structure and function. Nat Prod Rep. 2002, 19 (3): 312-331. 10.1039/b100916h.View ArticlePubMedGoogle Scholar
- Zsila F, Gedeon G: Binding of anti-prion agents to glycosaminoglycans: evidence from electronic absorption and circular dichroism spectroscopy. Biochem Biophys Res Commun. 2006, 346 (4): 1267-1274. 10.1016/j.bbrc.2006.06.033.View ArticlePubMedGoogle Scholar
- Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD, Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998, 102 (9): 1662-1673. 10.1172/JCI4105.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61 (14): 5562-5569.PubMedGoogle Scholar
- Sanderson RD: Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol. 2001, 12 (2): 89-98. 10.1006/scdb.2000.0241.View ArticlePubMedGoogle Scholar
- Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT: Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem. 1998, 273 (1): 51-57. 10.1074/jbc.273.1.51.View ArticlePubMedGoogle Scholar
- Safaiyan F, Lindahl U, Salmivirta M: Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem. 1998, 252 (3): 576-582. 10.1046/j.1432-1327.1998.2520576.x.View ArticlePubMedGoogle Scholar
- Mader JS, Salsman J, Conrad DM, Hoskin DW: Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 2005, 4 (4): 612-624. 10.1158/1535-7163.MCT-04-0077.View ArticlePubMedGoogle Scholar
- Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I: Bovine lactoferrin and Lactoferricin inhibit tumor metastasis in mice. Adv Exp Med Biol. 1998, 443: 285-291.View ArticlePubMedGoogle Scholar
- Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal O: Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 2004, 61 (2): 101-109. 10.1016/j.antiviral.2003.09.001.View ArticlePubMedGoogle Scholar
- Esko JD, Stewart TE, Taylor WH: Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci USA. 1985, 82 (10): 3197-3201. 10.1073/pnas.82.10.3197.View ArticlePubMedPubMed CentralGoogle Scholar
- Bai X, Wei G, Sinha A, Esko JD: Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. J Biol Chem. 1999, 274 (19): 13017-13024. 10.1074/jbc.274.19.13017.View ArticlePubMedGoogle Scholar
- Eliassen LT, Haug BE, Berge G, Rekdal O: Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J Pept Sci. 2003, 9 (8): 510-517. 10.1002/psc.472.View ArticlePubMedGoogle Scholar
- Keller KM, Brauer PR, Keller JM: Modulation of cell surface heparan sulfate structure by growth of cells in the presence of chlorate. Biochemistry. 1989, 28 (20): 8100-8107. 10.1021/bi00446a021.View ArticlePubMedGoogle Scholar
- Yanagishita M, Hascall VC: Proteoglycans synthesized by rat ovarian granulosa cells in culture. Isolation, fractionation, and characterization of proteoglycans associated with the cell layer. J Biol Chem. 1984, 259 (16): 10260-10269.PubMedGoogle Scholar
- Shively JE, Conrad HE: Formation of anhydrosugars in the chemical depolymerization of heparin. Biochemistry. 1976, 15 (18): 3932-3942. 10.1021/bi00663a005.View ArticlePubMedGoogle Scholar
- Greve H, Cully Z, Blumberg P, Kresse H: Influence of chlorate on proteoglycan biosynthesis by cultured human fibroblasts. J Biol Chem. 1988, 263 (26): 12886-12892.PubMedGoogle Scholar
- Uhlin-Hansen L, Yanagishita M: Differential effect of brefeldin A on the biosynthesis of heparan sulfate and chondroitin/dermatan sulfate proteoglycans in rat ovarian granulosa cells in culture. J Biol Chem. 1993, 268 (23): 17370-17376.PubMedGoogle Scholar
- Stringer SE, Gallagher JT: Heparan sulphate. Int J Biochem Cell Biol. 1997, 29 (5): 709-714. 10.1016/S1357-2725(96)00170-7.View ArticlePubMedGoogle Scholar
- Risso A, Zanetti M, Gennaro R: Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol. 1998, 189 (2): 107-115. 10.1006/cimm.1998.1358.View ArticlePubMedGoogle Scholar
- Schroder-Borm H, Bakalova R, Andra J: The NK-lysin derived peptide NK-2 preferentially kills cancer cells with increased surface levels of negatively charged phosphatidylserine. FEBS Lett. 2005, 579 (27): 6128-6134. 10.1016/j.febslet.2005.09.084.View ArticlePubMedGoogle Scholar
- Klaassen CD, Boles JW: Sulfation and sulfotransferases 5: the importance of 3'-phosphoadenosine 5'-phosphosulfate (PAPS) in the regulation of sulfation. Faseb J. 1997, 11 (6): 404-418.PubMedGoogle Scholar
- Safaiyan F, Kolset SO, Prydz K, Gottfridsson E, Lindahl U, Salmivirta M: Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem. 1999, 274 (51): 36267-36273. 10.1074/jbc.274.51.36267.View ArticlePubMedGoogle Scholar
- Zhang L, Lawrence R, Frazier BA, Esko JD: CHO glycosylation mutants: proteoglycans. Methods Enzymol. 2006, 416: 205-221. 10.1016/S0076-6879(06)16013-9.View ArticlePubMedGoogle Scholar
- Smetsers TF, Westerlo van de EM, ten Dam GB, Overes IM, Schalkwijk J, van Muijen GN, van Kuppevelt TH: Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J Invest Dermatol. 2004, 122 (3): 707-716. 10.1111/j.0022-202X.2004.22316.x.View ArticlePubMedGoogle Scholar
- Molist A, Romaris M, Lindahl U, Villena J, Touab M, Bassols A: Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. Eur J Biochem. 1998, 254 (2): 371-377. 10.1046/j.1432-1327.1998.2540371.x.View ArticlePubMedGoogle Scholar
- Guibinga GH, Miyanohara A, Esko JD, Friedmann T: Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther. 2002, 5 (5 Pt 1): 538-546. 10.1006/mthe.2002.0578.View ArticlePubMedGoogle Scholar
- Ueda M, Matsumoto S, Hayashi S, Kobayashi N, Noguchi H: Cell surface heparan sulfate proteoglycans mediate the internalization of PDX-1 protein. Cell Transplant. 2008, 17 (1–2): 91-97. 10.3727/000000008783906892.View ArticlePubMedGoogle Scholar
- Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992, 8: 365-393. 10.1146/annurev.cb.08.110192.002053.View ArticlePubMedGoogle Scholar
- Fransson LA: Glypicans. Int J Biochem Cell Biol. 2003, 35 (2): 125-129. 10.1016/S1357-2725(02)00095-X.View ArticlePubMedGoogle Scholar
- Tumova S, Woods A, Couchman JR: Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol. 2000, 32 (3): 269-288. 10.1016/S1357-2725(99)00116-8.View ArticlePubMedGoogle Scholar
- Rees SG, Hughes W, Embery G: Interaction of glucuronic acid and iduronic acid-rich glycosaminoglycans and their modified forms with hydroxyapatite. Biomaterials. 2002, 23 (2): 481-489. 10.1016/S0142-9612(01)00130-2.View ArticlePubMedGoogle Scholar
- Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L: Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol. 2002, 46 (1): 157-168. 10.1046/j.1365-2958.2002.03146.x.View ArticlePubMedGoogle Scholar
- Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A: Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J Antimicrob Chemother. 2006, 57 (2): 260-265. 10.1093/jac/dki460.View ArticlePubMedGoogle Scholar
- Schmidtchen A, Frick IM, Bjorck L: Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. Mol Microbiol. 2001, 39 (3): 708-713. 10.1046/j.1365-2958.2001.02251.x.View ArticlePubMedGoogle Scholar
- Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ: A wide range of medium-sized, highly cationic, alpha-helical peptides show antiviral activity against herpes simplex virus. Antiviral Res. 2004, 64 (2): 119-126.View ArticlePubMedGoogle Scholar
- Andersen JH, Jenssen H, Sandvik K, Gutteberg TJ: Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol. 2004, 74 (2): 262-271. 10.1002/jmv.20171.View ArticlePubMedGoogle Scholar
- Roseanu A, Chelu F, Trif M, Motas C, Brock JH: Inhibition of binding of lactoferrin to the human promonocyte cell line THP-1 by heparin: the role of cell surface sulphated molecules. Biochim Biophys Acta. 2000, 1475 (1): 35-38.View ArticlePubMedGoogle Scholar
- Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K: Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 2004, 279 (13): 12346-12354. 10.1074/jbc.M313523200.View ArticlePubMedGoogle Scholar
- Yuguchi Y, Kominato R, Ban T, Urakawa H, Kajiwara K, Takano R, Kamei K, Hara S: Structural observation of complexes of FGF-2 and regioselectively desulfated heparin in aqueous solutions. Int J Biol Macromol. 2005, 35 (1–2): 19-25. 10.1016/j.ijbiomac.2004.11.003.View ArticlePubMedGoogle Scholar
- Kusche M, Torri G, Casu B, Lindahl U: Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites. J Biol Chem. 1990, 265 (13): 7292-7300.PubMedGoogle Scholar
- Mahalingam Y, Gallagher JT, Couchman JR: Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties. J Biol Chem. 2007, 282 (5): 3221-3230. 10.1074/jbc.M604938200.View ArticlePubMedGoogle Scholar
- Rintala M, Inki P, Klemi P, Jalkanen M, Grenman S: Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol. 1999, 75 (3): 372-378. 10.1006/gyno.1999.5595.View ArticlePubMedGoogle Scholar
- Harada K, Masuda S, Hirano M, Nakanuma Y: Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Human Pathology. 2003, 34 (9): 857-863. 10.1016/S0046-8177(03)00336-8.View ArticlePubMedGoogle Scholar
- Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Takamori K, Igawa K, Yoshida M, Fukuyama H, Takahashi T, et al: Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma. J Oral pathol Med. 2006, 35 (5): 301-306. 10.1111/j.1600-0714.2006.00412.x.View ArticlePubMedGoogle Scholar
- Bame K: Heparanase: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 2001, 11 (6): 91-98. 10.1093/glycob/11.6.91R.View ArticleGoogle Scholar
- Ilan N, Elkin M, Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006, 38 (12): 2018-2039. 10.1016/j.biocel.2006.06.004.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/9/183/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.